Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
March 3rd, 2021
6.7K views
Crystallographic fragment screening at the Helmholtz-Zentrum Berlin is performed using a workflow with dedicated compound libraries, crystal handling tools, fast data collection facilities and largely automated data analysis. The presented protocol intends to maximize the output of such experiments to provide promising starting points for downstream structure-based ligand design.
Overview
This article discusses crystallographic fragment screening as a method for identifying potential drug candidates through x-ray crystallography. The protocol aims to enhance the efficiency of experiments by utilizing automated data analysis and optimized sample handling.
Key Study Components
Area of Science
- Crystallography
- Drug Discovery
- Biochemistry
Background
- Fragment screening is a technique used to identify small organic compounds that can bind to proteins.
- The quality of results is highly dependent on sample handling and crystallization techniques.
- This method can be applied to various biochemically relevant protein targets.
- Proper handling of crystals is crucial for successful data collection.
Purpose of Study
- To demonstrate a detailed protocol for crystallographic fragment screening.
- To provide insights into the binding characteristics of fragments on protein surfaces.
- To improve the output of experiments for structure-based ligand design.
Methods Used
- Preparation of screening plates with soaking solutions.
- Transfer of protein crystals to screening wells.
- Incubation of crystals under optimized conditions.
- Data collection and analysis using specialized software.
Main Results
- Identification of 15 hits on the AR protein complex under DMSO-free conditions.
- Comparison with previous experiments showed that omitting DMSO can still yield significant hits.
- Demonstrated variability in crystal morphologies and their impact on data quality.
Conclusions
- Crystallographic fragment screening is a valuable technique in drug discovery.
- Careful handling of crystals is essential for obtaining reliable data.
- The protocol can serve as a guide for researchers in academia and industry.
Frequently Asked Questions
What is crystallographic fragment screening?
It is a method used to identify small organic compounds that bind to proteins, aiding in drug discovery.
Why is sample handling important?
Proper sample handling ensures the quality of crystals, which is crucial for successful data collection.
What are the main steps in the protocol?
The protocol includes preparing screening plates, transferring crystals, incubating, and data collection.
How does DMSO affect the results?
Omitting DMSO can still yield significant hits, as shown in the study's results.
Who conducted the demonstration in the article?
Tatjana Barthel, a doctoral researcher, demonstrated the procedure.
Executive Industry Relevance
Crystallographic fragment screening enables early identification of ligand-binding modes with atomic resolution, supporting target validation and lead optimization in structure-based drug discovery. The workflow presented at HZB integrates automated data processing and standardized crystal handling to improve reproducibility and throughput in fragment hit finding. This approach reduces mechanistic uncertainty in early discovery by providing direct structural insights into fragment-protein interactions, informing go/no-go decisions for downstream medicinal chemistry efforts.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Provides direct 3D visualization of fragment binding sites, enabling mechanistic de-risking of target hypotheses.
- Operational Value: Supports rapid screening of 96-membered fragment libraries against protein crystals to interrogate binding site plasticity.
- Predictive Value: Identifies fragment hits that serve as starting points for structure-guided optimization of potent binders.
Screening & Assay Development
- Scientific Value: Delivers quantitative electron density maps to confirm fragment occupancy and binding conformation.
- Operational Value: Utilizes robot-mounted sample exchange at synchrotron beamlines for automated data collection across hundreds of crystals.
- Assay Readiness: Employs standardized soaking and flash-cooling protocols to ensure reproducible diffraction-quality data.
Translational & Preclinical Research
- Translational Continuity: Fragment hits identified via CFS can be evolved into leads with improved pharmacological properties for preclinical evaluation.
- Mechanistic De-risking: Structural data from fragment binding informs SAR development and reduces attrition risk in lead optimization.
- Preclinical Relevance: Enables assessment of fragment efficiency and ligand efficiency metrics to prioritize chemotypes with favorable developability.
Pipeline & Workflow Integration
The CFS workflow fits within the early discovery continuum, supporting target validation through structural characterization and enabling lead identification via fragment growing or linking strategies.
- Discovery Biology: Facilitates hypothesis testing by revealing where and how small molecules bind to protein targets of interest.
- Screening: Enables parallel screening of fragment libraries using automated crystal handling and synchrotron-based data collection.
- Analytics: Integrates XDSAPP, fspipeline, and PenDA for automated processing, refinement, and hit identification from diffraction datasets.
- Translational Research: Supports structure-based ligand design by providing atomic-level binding modes for fragment optimization.
- Enterprise Reuse: Establishes a standardized, reusable platform for fragment screening across multiple protein targets in a discovery portfolio.
Operational & Enterprise Impact
- Scientific Value: Increases confidence in target-ligand interactions through direct experimental evidence of binding mode.
- Operational Value: Enhances reproducibility via standardized crystal soaking, harvesting, and cryo-storage procedures.
- Strategic Value: Improves hit-to-lead efficiency by prioritizing fragments with favorable binding interactions for medicinal chemistry.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on fragment screening outcomes and structural tractability.
Implementation Considerations
- Requires expertise in protein crystallization, crystal handling, and synchrotron-based data collection.
- Dependent on access to high-brightness beamlines and automated sample changers for high-throughput screening.
- Necessitates standardized protocols for fragment library preparation, soaking conditions, and data analysis pipelines.
- Involves cross-team coordination between structural biology, medicinal chemistry, and data analysis groups.
- Limited to targets for which reproducible, high-quality crystals can be obtained and maintained under screening conditions.
Biopharma FAQs
Why does omitting DMSO in soaking solution affect hit identification?
Omitting DMSO in the soaking condition still enabled identification of 15 hits on the AR protein complex, representing 75% of the hits found in a previous screen that included DMSO. This indicates that fragment binding can be reliably detected without DMSO, reducing potential interference from the solvent in electron density maps.
How does independent variable isolation support target validation in fragment screening?
By controlling soaking conditions such as DMSO presence or absence, researchers can isolate the effect of the fragment on binding, enabling clearer interpretation of structure-activity relationships. This isolation helps distinguish true fragment binding from artifacts or non-specific interactions, increasing confidence in target engagement.
What quantitative measurements enable hit identification in crystallographic fragment screening?
Hit identification relies on the analysis of difference electron density maps to detect fragment occupancy at specific binding sites, quantified through refinement metrics and occupancy values. The PenDA software evaluates these maps to score potential hits based on density peak height and chemical plausibility.
Why do replication requirements matter for cross-functional collaboration in fragment screening?
Reproducible crystal harvesting and data collection across multiple wells ensure consistent data quality, enabling reliable comparison of results between experiments. This consistency allows structural biologists and medicinal chemists to align on hit validation and prioritization decisions using shared structural evidence.
What statistical analysis capabilities are required before implementing crystallographic fragment screening?
Implementation requires automated pipelines for diffraction data processing (XDSAPP), structure refinement (fspipeline), and hit finding (PenDA) to enable quantitative assessment of fragment binding. These tools provide statistical validation of electron density features, reducing false positives in hit identification.
